Download Image
    
Share
  
Post
Dimethyl fumarate for COVID-19
1 study with >700 patients
Hospital Icon Control
Hospital Icon Dimethyl fumarate Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Dimethyl fumarate studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -3% Mortality -3% RCTs -3% Late -3% Favorsdimethyl fumarate Favorscontrol
Recent:
Horby.
Sep 2
 Horby et al., medRxiv, doi:10.1101/2025.08.29.25334732 Long-term follow-up of treatment comparisons in RECOVERY: a randomised, open-label, platform trial for patients hospitalised with COVID-19
6-month followup of RECOVERY patients. Results are reported within the respective trials for each treatment.
Jan 31
2024
 Horby et al., Nature Communications, doi:10.1038/s41467-023-43644-x Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
3% higher mortality (p=0.89), 20% higher ventilation (p=0.65), and 12% worse 7-point scale results (p=0.41). RCT 713 hospitalized COVID-19 patients showing no significant difference in clinical outcomes with dimethyl fumarate. 6-month results are from [Horby]